The United States cell and gene therapy manufacturing QC market size was valued at USD 792.10 million in 2024 and is projected to grow from USD 994.08 million in 2025 to USD 6,117.49 million by 2033, exhibiting a CAGR of 25.5% during the forecast period (2025–2033).

The market is witnessing rapid growth due to increasing technological advancements in QC solutions, along with rising government and public initiatives supporting research and development in the cell and gene therapy sector. These factors are creating significant growth opportunities and accelerating innovation in quality control processes.

United States Cell and Gene Therapy Manufacturing QC Market Trends

Technological Advancements in QC Tools

Technological advancements are significantly transforming QC processes in the U.S. market. The integration of automation, next-generation sequencing (NGS), and real-time polymerase chain reaction (PCR) technologies has enhanced the accuracy, speed, and reliability of quality assessments.

These innovations enable precise genetic characterization, contaminant detection, and real-time monitoring, improving scalability and reducing operational costs. Companies are increasingly adopting digital and automated QC systems to enhance efficiency and compliance.

Market Summary

United States Cell and Gene Therapy Manufacturing QC Market Drivers

Technological Advancements in QC Tools

Advancements in QC technologies such as NGS and PCR are driving market growth by enabling precise analysis of gene-modified cells, improving contamination detection, and enhancing process reliability.

These innovations are helping companies scale operations efficiently while maintaining regulatory compliance.

Market Restraining Factors

Shortage of Skilled Personnel

A major challenge in the market is the shortage of skilled professionals with expertise in molecular biology, bioinformatics, and advanced QC technologies.

This talent gap increases operational costs and limits scalability, as companies must invest heavily in training or recruiting specialized professionals.

Market Opportunity

Government Funding and Public-Private Partnerships

Growing government support and funding initiatives are creating strong opportunities for market expansion. Programs led by organizations such as the NIH are supporting research projects focused on improving QC standards and manufacturing scalability.

Additionally, collaborations between academic institutions, government agencies, and private companies are accelerating innovation and enabling the development of advanced QC frameworks.

Regional (Country-Level) Insights

The United States dominates the global market due to its strong presence in cell and gene therapy R&D, advanced infrastructure, and supportive regulatory environment.

• Massachusetts (Boston-Cambridge): A major biotech hub with over 1,000 companies contributing significantly to the global gene therapy pipeline.

• California (San Francisco & San Diego): Strong growth driven by venture capital investments and innovation in gene therapy.

• North Carolina (Research Triangle Park): Emerging hub attracting multiple gene therapy companies due to favorable business conditions.

• Texas (Houston): Growing prominence with institutions like MD Anderson Cancer Center supporting clinical trials and innovation.

These regions collectively drive demand for advanced QC technologies and services in the U.S.

Segmental Analysis

By Process

• Upstream Processes (Dominant, CAGR ~25.3%)

• Downstream Processes

By End-User

• Biopharmaceutical / Biotechnological Companies (Dominant, CAGR ~25.2%)

• Pharmaceutical Companies

• Contract Manufacturing Organizations

By Technology Type

• Polymerase Chain Reaction (PCR) (Dominant, CAGR ~26.0%)

• Fluorescence-Activated Cell Sorting (FACS)

• Enzyme-Linked Immunosorbent Assay (ELISA)

• Chromatography

• Next-Generation Sequencing (NGS)

• Others

Purchase Exclusive Premium Reports Now @ https://straitsresearch.com/buy-now/cell-and-gene-therapy-manufacturing-qc-market/united-states

Key Market Players

• Lonza

• Pharmaron

• Eurofins Scientific

• Merck KGaA

• Catalent Inc.

• Charles River Laboratories

• Thermo Fisher Scientific Inc.

• WuXi AppTec

• BioAgilytix Labs

• Alcami Corporation

• IQVIA Inc.

• SGS Société Générale de Surveillance SA

Analyst Opinion

The U.S. market is expected to experience robust growth, driven by technological innovation, regulatory requirements, and increasing investments in infrastructure. The integration of QC processes into manufacturing workflows will enhance efficiency, reduce costs, and improve product quality.

Companies focusing on scalable, automated, and compliant QC solutions are likely to gain a competitive edge as the market continues to expand alongside the growth of the cell and gene therapy industry.